CELADON PHARMACEUTICALS PLC Logo

CELADON PHARMACEUTICALS PLC

Researches, cultivates, and manufactures cannabinoid-based medicines for chronic pain.

CEL | IL

Overview

Corporate Details

ISIN(s):
GB00BDQYGP38
LEI:
213800YXCATORT475807
Country:
United Kingdom
Address:
32-33 COWCROSS STREET, EC1M 6DF LONDON

Description

Celadon Pharmaceuticals PLC is a vertically integrated pharmaceutical company focused on the research, cultivation, manufacturing, and supply of cannabinoid-based medicines. The company operates a licensed, 100,000 sq ft facility with EU-GMP certification for the indoor, hydroponic cultivation of high-THC cannabis and the extraction of cannabinoid Active Pharmaceutical Ingredients (API). Its primary focus is the chronic pain market, and it is conducting an MHRA conditionally approved clinical trial to generate data supporting the use of its medicines for this condition. Additionally, Celadon has an in-house research and development program focused on intellectual property generation and is involved in developing a licensed cannabinoid treatment for Autism Spectrum Disorder through a biopharma partnership.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-28 17:10
Result of General Meeting
English 20.4 KB
2025-07-02 08:00
Proposed Cancellation
English 99.3 KB
2025-07-01 12:48
Funding Update
English 10.8 KB
2025-07-01 09:20
Result of AGM
English 24.0 KB
2025-06-30 08:00
Funding and Operational Update, Delay in Results
English 22.5 KB
2025-06-11 08:00
New Committed Credit Facility
English 14.2 KB
2025-06-06 16:55
Funding Update, Notice of AGM
English 12.1 KB
2025-05-30 19:07
Funding Update
English 11.3 KB
2025-03-19 08:00
Funding Update
English 11.8 KB
2025-02-26 14:00
New Committed Credit Facility
English 15.5 KB
2025-02-12 08:00
Finance Update
English 10.4 KB
2025-01-31 08:00
Finance Update
English 10.7 KB
2025-01-16 08:00
Update on Strategic Collaboration
English 13.7 KB
2025-01-02 08:00
Funding Update
English 10.6 KB
2024-12-20 08:00
Finance Update
English 10.8 KB

Automate Your Workflow. Get a real-time feed of all CELADON PHARMACEUTICALS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CELADON PHARMACEUTICALS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CELADON PHARMACEUTICALS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.